{"search_session":{},"preferences":{"l":"en","queryLanguage":"en"},"patentId":"US_2013_0064794_A1","frontPageModel":{"patentViewModel":{"ref":{"entityRefId":"103-484-440-694-471","entityRefType":"PATENT"},"entityMetadata":{"linkedIds":{"empty":false},"tags":[],"collections":[{"id":11855,"type":"PATENT","title":"University of Montpellier Patent Portfolio","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":11808,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[{"id":8467,"type":"COLLECTION","user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"text":"
Search Applicants and Owners separately:univ* AND Montpellier. Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 1289
Search Applicants and Owners separately:univ* AND Montpellier. Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 1289
R is a moiety derivable by removal of a hydrogen radical from a hydroxy group of an antiviral drug;\n
Q is —N(Rγ)—, —O—, —S— or —C(Rγ)2—;\n
X is O or S;\n
each Rγ is independently hydrogen or alkyl;\n
each R3 and R3′ is independently hydrogen or alkyl; or R3 and R3′ together with the carbon atom to which they are attached form a 3-7 membered ring;\n
R1 and R2 are selected as follows:\n
i) R1 and R2 are each independently hydrogen, alkyl, alkenyl, alkynyl, aryl, aralkyl, cycloalkyl, cycloalkenyl, alkylheterocyclyl or alkylheteroaryl;\n
ii) R1 and R2 together with the nitrogen atom on which they are substituted form a 3-7 membered heterocyclic or heteroaryl ring, wherein the ring is unsubstituted or substituted by C(O)Q1; or\n
iii) R1 is hydrogen, alkyl or cycloalkyl, and R2 is -(G)mC(O)Q1;\n
Q1 is OR4, SR4 or NR5R6;\n
each G is independently CR7R8; and\n
each m is 1 or 2;\n
R4 is alkyl, alkenyl, alkynyl, aryl, aralkyl, cycloalkyl or cycloalkenyl;\n
R5 and R6 are selected as follows:\n
i) R5 and R6 are each independently hydrogen, alkyl, alkenyl, alkynyl, aryl, aralkyl, cycloalkyl or cycloalkenyl; or\n
ii) R5 and R6 together with the nitrogen atom on which they are substituted form a 3-7 membered heterocyclic or heteroaryl ring; and\n
R7 and R8 are selected as follows:\n
i) R7 and R8 are each independently hydrogen, alkyl, heteroalkyl, alkenyl, heteroalkenyl, alkynyl, heteroalkynyl, aryl, aralkyl, heteroaryl, heteroaralkyl, cycloalkyl, cycloalkenyl, alkylheterocyclyl or alkylheteroaryl, wherein alkyl is optionally substituted by alkoxy; or\n
ii) R7 and R8 together with the carbon atom to which they are attached form a 3-7 membered cycloalkyl ring."],"number":1,"annotation":false,"claim":true,"title":false},{"lines":["The compound of claim 1 wherein Q is —O— or —C(Rγ)2—."],"number":2,"annotation":false,"claim":true,"title":false},{"lines":["The compound of claim 1 wherein each Rγ is independently hydrogen, methyl, ethyl, propyl or isopropyl."],"number":3,"annotation":false,"claim":true,"title":false},{"lines":["The compound of claim 1 wherein each R3 and R3′ is independently hydrogen, methyl, ethyl, propyl or isopropyl."],"number":4,"annotation":false,"claim":true,"title":false},{"lines":["The compound of claim 1 wherein R1 is hydrogen."],"number":5,"annotation":false,"claim":true,"title":false},{"lines":["The compound of claim 1 wherein R1 is hydrogen and R2 is benzyl."],"number":6,"annotation":false,"claim":true,"title":false},{"lines":["The compound of claim 1 wherein R1 is hydrogen and R2 is —CR7R8C(O)OR4."],"number":7,"annotation":false,"claim":true,"title":false},{"lines":["The compound of claim 1 wherein R7 is hydrogen, R8 is alkyl or heteroalkyl and R4 is alkyl."],"number":8,"annotation":false,"claim":true,"title":false},{"lines":["The compound of claim 1, wherein, when R1 and R2 together with the nitrogen to which they are attached form at least one L-amino acid residue, or an ester thereof."],"number":9,"annotation":false,"claim":true,"title":false},{"lines":["The compound of any one of claims 1 to 9, wherein R is a moiety derivable by removal of a hydrogen radical from a hydroxy group of a compound selected from ribavirin, viramidine, valopicitabine, PSI-6130, PSI-6206, PSI-938 and R1479."],"number":10,"annotation":false,"claim":true,"title":false},{"lines":["A compound of Formula II:\nor a pharmaceutically acceptable salt, stereoisomeric, tautomeric or polymorphic form thereof, wherein:\n
Base is a substituted or unsubstituted purine or pyrimidine;\n
Q is —N(Rγ) —, —O—, —S— or —C(Rγ)2—;\n
U is hydrogen, C1-6 alkyl, C2-6 alkenyl or C2-6 alkynyl;\n
W is alkyl, cycloalkyl, alkenyl, cycloalkenyl or alkynyl;\n
Z is hydrogen, OR10, SR10, NR5R6, F, Cl, Br or I; or W and Z, together with the carbon to which they are attached, join to form a 3 to 7 membered cyclic or heterocyclic ring;\n
X is O or S;\n
Y is hydrogen or OR9;\n
each Rγ is independently hydrogen or alkyl;\n
each R3 and R3′ is independently hydrogen or alkyl; or R3 and R3′ together with the carbon atom to which they are attached form a 3-7 membered ring;\n
R1 and R2 are selected as follows:\n
i) R1 and R2 are each independently hydrogen, alkyl, alkenyl, alkynyl, aryl, aralkyl, cycloalkyl, cycloalkenyl, alkylheterocyclyl or alkylheteroaryl;\n
ii) R1 and R2 together with the nitrogen atom on which they are substituted form a 3-7 membered heterocyclic or heteroaryl ring, wherein the ring is unsubstituted or substituted by C(O)Q1; or\n
iii) R1 is hydrogen, alkyl or cycloalkyl, and R2 is -(G)mC(O)Q1;\n
Q1 is OR4, SR4 or NR5R6;\n
each G is independently CR7R8; and\n
each m is 1 or 2;\n
R4 is alkyl, alkenyl, alkynyl, aryl, aralkyl, cycloalkyl or cycloalkenyl;\n
R5 and R6 are selected as follows:\n
i) R5 and R6 are each independently hydrogen, alkyl, alkenyl, alkynyl, aryl, aralkyl, cycloalkyl or cycloalkenyl; or\n
ii) R5 and R6 together with the nitrogen atom on which they are substituted form a 3-7 membered heterocyclic or heteroaryl ring; and\n
R7 and R8 are selected as follows:\n
i) R7 and R8 are each independently hydrogen, alkyl, heteroalkyl, alkenyl, heteroalkenyl, alkynyl, heteroalkynyl, aryl, aralkyl, heteroaryl, heteroaralkyl, cycloalkyl, cycloalkenyl, alkylheterocyclyl or alkylheteroaryl, wherein alkyl is optionally substituted by alkoxy; or\n
ii) R7 and R8 together with the carbon atom to which they are attached form a 3-7 membered cycloalkyl ring; and\n
R9 and R10 are selected as follows:\n
i) R9 and R10 are each independently hydrogen, alkyl, alkenyl, alkynyl, aryl, aralkyl, cycloalkyl or cycloalkenyl; or\n
ii) R9 and R10 together with a C(O) and the oxygen or sulfur atoms on which they are substituted form a 5 membered ring."],"number":11,"annotation":false,"claim":true,"title":false},{"lines":["The compound of claim 11, wherein U is hydrogen, Y is OR9 and Z is OR10 or F."],"number":12,"annotation":false,"claim":true,"title":false},{"lines":["The compound of claim 11, wherein U is hydrogen and W is alkyl, alkenyl or alkynyl."],"number":13,"annotation":false,"claim":true,"title":false},{"lines":["The compound of claim 11, wherein W is alkyl."],"number":14,"annotation":false,"claim":true,"title":false},{"lines":["The compound of claim 11, wherein U is hydrogen, W is ethynyl; Y is OR9; Z is F; and R9 is hydrogen."],"number":15,"annotation":false,"claim":true,"title":false},{"lines":["The compound of claim 11, wherein U is hydrogen, W is methyl; Y is OR9; Z is F; and R9 is hydrogen."],"number":16,"annotation":false,"claim":true,"title":false},{"lines":["The compound of claim 11, wherein U is hydrogen, W is methyl; Y is OR9; Z is OR10; and R9 and R10 are each hydrogen."],"number":17,"annotation":false,"claim":true,"title":false},{"lines":["The compound of claim 11, wherein Q is —O— or —C(Rγ)2—."],"number":18,"annotation":false,"claim":true,"title":false},{"lines":["The compound of claim 11, wherein each Rγ is independently hydrogen, methyl, ethyl, propyl or isopropyl."],"number":19,"annotation":false,"claim":true,"title":false},{"lines":["The compound of claim 11, wherein each R3 and R3′ is independently hydrogen, methyl, ethyl, propyl or isopropyl."],"number":20,"annotation":false,"claim":true,"title":false},{"lines":["The compound of claim 11, wherein R1 is hydrogen."],"number":21,"annotation":false,"claim":true,"title":false},{"lines":["The compound of claim 11, wherein R1 is hydrogen and R2 is benzyl."],"number":22,"annotation":false,"claim":true,"title":false},{"lines":["The compound of claim 11, wherein R1 is hydrogen and R2 is —CR7R8C(O)OR4."],"number":23,"annotation":false,"claim":true,"title":false},{"lines":["The compound of claim 11, wherein R7 is hydrogen, R8 is alkyl or heteroalkyl and R4 is alkyl."],"number":24,"annotation":false,"claim":true,"title":false},{"lines":["The compound of claim 11, wherein, when R1 and R2 together with the nitrogen to which they are attached form at least one L-amino acid residue, or an ester thereof."],"number":25,"annotation":false,"claim":true,"title":false},{"lines":["The compound of claim 11, wherein Base is adenine, cytosine, guanine, hypoxanthine, thymine or uracil."],"number":26,"annotation":false,"claim":true,"title":false},{"lines":["The compound of claim 26, wherein Base is cytosine."],"number":27,"annotation":false,"claim":true,"title":false},{"lines":["The compound of claim 26, wherein Base is guanine."],"number":28,"annotation":false,"claim":true,"title":false},{"lines":["The compound of claim 26, wherein Base is uracil."],"number":29,"annotation":false,"claim":true,"title":false},{"lines":["The compound of claim 11, wherein Base is selected from one of formulae (I) to (xxvii):\n\n\n\n\nwherein:\n
each RL is independently hydrogen, alkyl, cycloalkyl, acyl, carbamyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, sulfonate ester, alkyl sulfonyl, aryl sulfonyl, arylalkyl sulfonyl, a lipid, a phospholipid, an amino acid or a carbohydrate; and\n
each RM and RN is independently hydrogen or alkyl; or RL and RM together with the N atom to which they are attached from heterocyclyl."],"number":30,"annotation":false,"claim":true,"title":false},{"lines":["The compound of claim 30, wherein RL is hydrogen, alkyl or cycloalkyl."],"number":31,"annotation":false,"claim":true,"title":false},{"lines":["The compound of claim 30, wherein RL is cyclopropyl or cyclopentyl."],"number":32,"annotation":false,"claim":true,"title":false},{"lines":["The compound of claim 30, wherein RL is methyl, ethyl, propyl or isopropyl."],"number":33,"annotation":false,"claim":true,"title":false},{"lines":["The compound of claim 30, wherein RM is hydrogen."],"number":34,"annotation":false,"claim":true,"title":false},{"lines":["The compound of claim 30, wherein RM is methyl."],"number":35,"annotation":false,"claim":true,"title":false},{"lines":["A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable excipient, carrier or diluent."],"number":36,"annotation":false,"claim":true,"title":false},{"lines":["The pharmaceutical composition of claim 36, wherein the composition is an oral formulation."],"number":37,"annotation":false,"claim":true,"title":false},{"lines":["A pharmaceutical composition comprising a compound of claim 11 and a pharmaceutically acceptable excipient, carrier or diluent."],"number":38,"annotation":false,"claim":true,"title":false},{"lines":["The pharmaceutical composition of claim 38, wherein the composition is an oral formulation."],"number":39,"annotation":false,"claim":true,"title":false},{"lines":["A method for the treatment of a host infected with a hepatitis C virus, comprising the administration of an effective treatment amount of a compound of claim 1."],"number":40,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 40, wherein the host is a human."],"number":41,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 40, wherein said administration directs a substantial amount of said compound or pharmaceutically acceptable salt or stereoisomer thereof to the liver of said host."],"number":42,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 40, wherein said compound or composition is administered in combination or alternation with a second anti-viral agent optionally selected from the group consisting of interferon, a nucleotide analogue, a polymerase inhibitor, an NS3 protease inhibitor, an NS5A inhibitor, an entry inhibitor, a non-nucleoside polymerase inhibitor, a cyclosporine immune inhibitor, an NS4A antagonist, an NS4B-RNA binding inhibitor, a locked nucleic acid mRNA inhibitor, a cyclophilin inhibitor, and combinations thereof."],"number":43,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 43, wherein the second anti-viral agent is selected from the group consisting of telaprevir, bocepravir, interferon alfacon-1, interferon alfa-2b, pegylated interferon alpha 2a, pegylated interferon alpha 2b, ribavirin, and combinations thereof."],"number":44,"annotation":false,"claim":true,"title":false},{"lines":["A method for the treatment of a host infected with a hepatitis C virus, comprising the administration of an effective treatment amount of a compound of claim 11."],"number":45,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 45, wherein the host is a human."],"number":46,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 45, wherein said administration directs a substantial amount of said compound or pharmaceutically acceptable salt or stereoisomer thereof to the liver of said host."],"number":47,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 45, wherein said compound or composition is administered in combination or alternation with a second anti-viral agent optionally selected from the group consisting of interferon, a nucleotide analogue, a polymerase inhibitor, an NS3 protease inhibitor, an NS5A inhibitor, an entry inhibitor, a non-nucleoside polymerase inhibitor, a cyclosporine immune inhibitor, an NS4A antagonist, an NS4B-RNA binding inhibitor, a locked nucleic acid mRNA inhibitor, a cyclophilin inhibitor, and combinations thereof."],"number":48,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 48, wherein the second anti-viral agent is selected from the group consisting of telaprevir, bocepravir, interferon alfacon-1, interferon alfa-2b, pegylated interferon alpha 2a, pegylated interferon alpha 2b, ribavirin, and combinations thereof."],"number":49,"annotation":false,"claim":true,"title":false}]}},"filters":{"npl":[],"notNpl":[],"applicant":[],"notApplicant":[],"inventor":[],"notInventor":[],"owner":[],"notOwner":[],"tags":[],"dates":[],"types":[],"notTypes":[],"j":[],"notJ":[],"fj":[],"notFj":[],"classIpcr":[],"notClassIpcr":[],"classNat":[],"notClassNat":[],"classCpc":[],"notClassCpc":[],"so":[],"notSo":[],"sat":[]},"sequenceFilters":{"s":"SEQIDNO","d":"ASCENDING","p":0,"n":10,"sp":[],"si":[],"len":[],"t":[],"loc":[]}}